Two River was founded by
Peter M. Kash,
Joshua A. Kazam, and
David M. Tanen, three partners who have worked together for nearly a decade and who possess more than 35 years of collective industry experience. Together, they have founded or financed more than 30 public and private drug development companies, many of which have filed new drug applications (NDA) with the FDA and have reached approval or have entered into strategic partnerships with major pharmaceutical and leading biotechnology companies.
The Two River team is completed by a staff of experienced MD's and PhD's as well as investment banking, finance, and business development specialists. Our dedicated team of experts evaluates technologies, structures and consummates complicated transactions and provides effective management and support for our portfolio of companies.
Two River also draws upon the knowledge and experience of a world class
Advisory Board comprised of thought leaders from preeminent research institutions including Memorial Sloan-Kettering Cancer Center, Columbia University, University of California at Los Angeles, University of Southern California and The Wharton School of Business. Their active involvement in the medical and academic communities makes them an invaluable component of Two River's team.
We believe that Two River's comprehensive scientific, financial and business expertise helps to ensure that our portfolio companies receive operational guidance and access to capital throughout all stages of development. Our value is being able to selectively identify and acquire technologies, create portfolio companies focusing on the development of these technologies, guide the operations of those companies and provide the financial resources required for them to advance. In the end, our success is measured by the success of our portfolio companies.